BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15308760)

  • 1. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
    Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
    Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants of HERG channel block by clofilium and ibutilide.
    Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
    Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants for high-affinity block of hERG potassium channels.
    Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
    Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of HERG channel block.
    Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
    Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
    Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
    Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
    Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular determinants of dofetilide block of HERG K+ channels.
    Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
    Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
    Chen J; Seebohm G; Sanguinetti MC
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
    Zhang P; Xing J; Luo A; Feng J; Liu Z; Gao C; Ma J
    J Pharm Pharmacol; 2013 Sep; 65(9):1321-8. PubMed ID: 23927470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
    Ridley JM; Milnes JT; Witchel HJ; Hancox JC
    Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.
    Madeja M; Leicher T; Friederich P; Punke MA; Haverkamp W; Musshoff U; Breithardt G; Speckmann EJ
    Mol Pharmacol; 2003 Mar; 63(3):547-56. PubMed ID: 12606761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.
    Thai KM; Windisch A; Stork D; Weinzinger A; Schiesaro A; Guy RH; Timin EN; Hering S; Ecker GF
    ChemMedChem; 2010 Mar; 5(3):436-42. PubMed ID: 20146282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
    Sánchez-Chapula JA; Navarro-Polanco RA; Culberson C; Chen J; Sanguinetti MC
    J Biol Chem; 2002 Jun; 277(26):23587-95. PubMed ID: 11960982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
    Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
    J Mol Cell Cardiol; 2004 May; 36(5):701-5. PubMed ID: 15135665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
    Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
    Ficker E; Jarolimek W; Brown AM
    Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
    Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
    Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
    Zitron E; Kiesecker C; Scholz E; Lück S; Bloehs R; Kathöfer S; Thomas D; Kiehn J; Kreye VA; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):146-56. PubMed ID: 15322737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
    Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.